Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10415): 1835-1847, 2023 11 18.
Article
in En
| MEDLINE
| ID: mdl-37871608
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Limits:
Adult
/
Humans
Language:
En
Journal:
Lancet
Year:
2023
Document type:
Article
Affiliation country:
China
Country of publication:
Reino Unido